E-Pharmacy Startup PlatinumRx Bags $6 Mn Series A Funding

The capital will be used to expand PlatinumRX’s network of fulfilment centres, build technology and product capabilities, and strengthen supply chain operations.

Bengaluru-based online pharmacy PlatinumRx has secured $6 Mn in a Series A funding round led by Stellaris Venture Partners, with participation from existing investor India Quotient.

The startup said the capital will be used to expand its network of fulfilment centres, build technology and product capabilities, and strengthen supply chain operations.

According to regulatory filings and startup statements, the round closed in late August 2025 and was announced on 3 September.

Although PlatinumRx and Stellaris have not disclosed the valuation or equity dilution yet.

Founded in 2024, PlatinumRx positions itself as a digital-first pharmacy with a focus on chronic-care patients who require recurring medication.

The platform differentiates itself by recommending lower-cost generic and substitute medicines, with an emphasis on affordability in a price-sensitive market. Customers can upload prescriptions, order medicines, and access teleconsultation through its platform.

The fresh capital will allow PlatinumRx to increase its “dark store” network across major Indian cities. Dark stores are fulfillment hubs that enable faster delivery and better control of inventory compared to third-party pharmacy tie-ups.

The startup has not disclosed how many such facilities it currently operates or the planned target number after expansion.

Beyond logistics, PlatinumRx plans to expand its product and engineering teams to improve the platform’s user experience, personalisation, and recommendation algorithms. The brand also intends to invest in marketing and customer acquisition to grow its user base.

Prior to this round, PlatinumRx had raised a seed investment of about USD 800,000 in April 2024 from India Quotient and a group of angel investors. The latest Series A significantly increases its funding base and gives it capital to compete with larger incumbents in the e-pharmacy space.

The startup claims its model helps patients save a substantial percentage on recurring prescriptions by offering cheaper but equivalent alternatives.

However, it has not released independent data to support these claims. Nor has it shared customer acquisition cost, repeat order rate, or unit economics that would demonstrate sustainable growth.

Industry observers note that regulatory compliance remains a key issue for all e-pharmacies. The Drugs and Cosmetics Act requires valid prescriptions and licensed distribution, and companies must ensure that generic substitutions meet legal and medical guidelines.

PlatinumRx has not disclosed details of its regulatory framework or prescription verification processes.

While the fresh funding signals investor confidence, unanswered questions remain around valuation, financial health, and operational scale.

PlatinumRx’s next phase of growth will depend on how effectively it can expand fulfillment capacity, lower delivery costs, and retain chronic-care patients in a crowded and highly regulated market.

Stay tuned for more such updates on Digital Health News